CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
Coronary Sinus Reducer device +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04121845
NCT04121845N/ACompleted

The Influence of Coronary Sinus Reducer Implantation on Exertional Capacity, Extent of Myocardial Ischemia and hrECG Markers of Arrhythmogenicity in Patients With Refractory Angina Pectoris

University Medical Centre Ljubljana·interventional·Posted Oct 10, 2019·Updated Jul 25, 2022

In Brief

A clinical study evaluating Coronary Sinus Reducer device and Sham procedure for Refractory Angina Pectoris. Completed, enrolled 25 participants across 1 site.

Detailed Summary

Patients with refractory angina pectoris have low quality of life and reduced exertional capacity. Studies have shown that the coronary sinus reducer (CSR) implantation improves the quality of life. However, to date there are no firm objective data on improvement of exertional capacity. Studies have shown a large influence of placebo effect after interventional procedures, which is even more pronounced than in medically treated patients. As angina pectoris presents entirely subjective perception of chest discomfort, its improvement may be influenced by this effect in up to 30 %. The investigators will study weather the CSR implantation improves aerobic exertional capacity in comparison to optimal medical therapy alone. Further, the investigators will explore the extent of myocardial reversible ischemia reduction and possible influence on hrECG markers of left ventricular arrhythmogenicity. 40 patients with refractory angina CCS class (Canadian cardiovascular society) II-IV and confirmed reversible ischemia will be included. Patients will be randomized into two groups. The first group will undergo CSR implantation procedure. The second group will present a sham control group with placebo procedure. At inclusion and after 6 months the investigators will perform cardiopulmonary exercise test (CPET), single photon emission tomography for detection of reversible ischemia (SPECT), high resolution ECG (hrECG), echocardiography and asses the subjective burden of angina according to CCS score and the quality of life according to the Seattle angina Questionnaire (SAQ).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSlovenia
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 10, 2019
Enrollment StartJan 1, 2019
Primary CompletionDec 31, 2021
Study CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 6.7 years ago

Interventions

Coronary Sinus Reducer devicedevice

Coronary sinus reducer device (Neovasc, Richomnd, Canada) implantation in the coronary sinus. The procedure is performed in the cardiac catheterization laboratory through right internal jugular vein.

Sham procedureother

Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.